Literature DB >> 25586325

A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials.

Amy S Nowacki1, Wenle Zhao2, Yuko Y Palesch2.   

Abstract

Response-adaptive randomization (RAR) offers clinical investigators benefit by modifying the treatment allocation probabilities to optimize the ethical, operational, or statistical performance of the trial. Delayed primary outcomes and their effect on RAR have been studied in the literature; however, the incorporation of surrogate outcomes has not been fully addressed. We explore the benefits and limitations of surrogate outcome utilization in RAR in the context of acute stroke clinical trials. We propose a novel surrogate-primary (S-P) replacement algorithm where a patient's surrogate outcome is used in the RAR algorithm only until their primary outcome becomes available to replace it. Computer simulations investigate the effect of both the delay in obtaining the primary outcome and the underlying surrogate and primary outcome distributional discrepancies on complete randomization, standard RAR and the S-P replacement algorithm methods. Results show that when the primary outcome is delayed, the S-P replacement algorithm reduces the variability of the treatment allocation probabilities and achieves stabilization sooner. Additionally, the S-P replacement algorithm benefit proved to be robust in that it preserved power and reduced the expected number of failures across a variety of scenarios.

Entities:  

Keywords:  Response-adaptive randomization; clinical trials; randomization; surrogate endpoints; unequal allocation

Mesh:

Substances:

Year:  2015        PMID: 25586325      PMCID: PMC4499496          DOI: 10.1177/0962280214567142

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  14 in total

1.  Optimal adaptive designs for binary response trials.

Authors:  W F Rosenberger; N Stallard; A Ivanova; C N Harper; M L Ricks
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

Review 2.  Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice.

Authors:  P W Duncan; H S Jorgensen; D T Wade
Journal:  Stroke       Date:  2000-06       Impact factor: 7.914

3.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

4.  The Interventional Management of Stroke (IMS) II Study.

Authors: 
Journal:  Stroke       Date:  2007-05-24       Impact factor: 7.914

5.  An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project.

Authors:  William J Meurer; Roger J Lewis; Danilo Tagle; Michael D Fetters; Laurie Legocki; Scott Berry; Jason Connor; Valerie Durkalski; Jordan Elm; Wenle Zhao; Shirley Frederiksen; Robert Silbergleit; Yuko Palesch; Donald A Berry; William G Barsan
Journal:  Ann Emerg Med       Date:  2012-03-15       Impact factor: 5.721

6.  The randomization and stratification of patients to clinical trials.

Authors:  M Zelen
Journal:  J Chronic Dis       Date:  1974-09

7.  Use of the Barthel index and modified Rankin scale in acute stroke trials.

Authors:  G Sulter; C Steen; J De Keyser
Journal:  Stroke       Date:  1999-08       Impact factor: 7.914

8.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

9.  Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.

Authors: 
Journal:  Stroke       Date:  2004-03-11       Impact factor: 7.914

10.  An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success.

Authors:  Roger J Lewis; Kert Viele; Kristine Broglio; Scott M Berry; Alan E Jones
Journal:  Crit Care Med       Date:  2013-07       Impact factor: 7.598

View more
  3 in total

1.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

2.  Stroke Recovery and Rehabilitation Research: Issues, Opportunities, and the National Institutes of Health StrokeNet.

Authors:  Steven C Cramer; Steven L Wolf; Harold P Adams; Daofen Chen; Alexander W Dromerick; Kari Dunning; Caitlyn Ellerbe; Andrew Grande; Scott Janis; Maarten G Lansberg; Ronald M Lazar; Yuko Y Palesch; Lorie Richards; Elliot Roth; Sean I Savitz; Lawrence R Wechsler; Max Wintermark; Joseph P Broderick
Journal:  Stroke       Date:  2017-02-07       Impact factor: 7.914

3.  The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  Trials       Date:  2020-06-17       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.